New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A July 11, 2022July 11, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Interim data from phase III HAVEN 6 study…Early treatment with Roche's OCREVUS leads to…European Commission approves label expansion of…CHMP recommends expansion of EU label for Hemlibra…New data reinforce the benefit of early preventative…New data for Roche’s Evrysdi (risdiplam) demonstrate…
